• Ramdam

  Led · Seed · Oct 2024

  Ramdam is an AI-powered platform that automates production of user-generated content (UGC) for advertisers, using AI to match advertisers with creators and streamline briefs, contracts, delivery, and invoicing. The platform sources and analyzes creators across TikTok, Instagram, and YouTube and operates a network of more than 50,000 creators across 50 countries and 10 languages. Ramdam produces over 1,000 video ads monthly and has partnered with more than 100 clients, including brands like Allianz and Voodoo. Founded in 2023 by Xavier de Baillenx, Emmanuel Lemoine, and Benjamin Combes, the team built the product after succeeding with a creator-driven growth campaign for a prior mobile app. The founders previously ran Pretty Fun Therapy, which was acquired by Match Group. The company plans to use the $3.15M seed financing to drive technological advancements and expand in the U.S. and Europe, and it sees potential to extend its approach beyond UGC to other creator types.

• L'Atout

  Participated · Equity · Mar 2024

  Founded in 2023, L'Atout builds a centralized application paired with an innovative payment solution to simplify the management and use of employee benefits (tickets restaurant, chèques vacances, discounted stays, etc.). The product aims to increase uptake of underused benefits by making them more accessible and easier to use for employees and clearer to employers. In six months the startup has onboarded about twenty SMEs, demonstrating early market traction. The company recently completed a €2 million financing round composed of €1.4 million in equity and €600,000 in debt. Proceeds will fund technological and commercial development, broaden the range of benefits offered, and support marketing and sales efforts. L'Atout also plans to recruit talent in technology, marketing and customer relations and is considering future European expansion.

• Welinq

  Participated · Seed · Jan 2023

  Welinq is a quantum-tech company specializing in hardware that links separate neutral-atom quantum processing units (QPUs) into a single, larger computer. Its flagship offering is a high-rate entanglement generation platform—described as a “quantum Ethernet port”—that converts qubit information into photons and distributes it between processors. The firm also claims to operate the most powerful neutral-atom-based quantum memory demonstrated to date, already validated through its first commercial sale. Welinq’s technology aligns natively with neutral-atom systems, operating at compatible optical wavelengths and allowing seamless integration from computing to networking. Through the new InterQo project it will collaborate with Pasqal to embed networking capability and efficient photon-extraction interfaces directly into future QPUs. The ultimate goal is to deploy scalable, fault-tolerant, networked quantum computers inside data-center environments worldwide. Financially, Welinq has just secured €4 million in non-dilutive France 2030 funding to advance this roadmap.

• Serious Factory

  Participated · Equity · Mar 2018

  Serious Factory, founded in 2012 and based in Suresnes, France, provides the Virtual Training Suite™ (VTS), a platform of serious games and training simulators. Its solutions enable customers to independently design, distribute, and update pedagogical content and include tools for monitoring skills and perpetuating professional achievements. The company focuses on helping users acquire the behavioral skills required by the job market across industries. It serves more than 150 companies in over 15 countries. The firm raised €3m in its second funding round and plans to use the capital to expand its pedagogical experts and sales teams. Backers include Odyssée Venture and historical investors such as the Paris Region Venture Fund (managed by CapDecisif Management) and SIBESSOR2/INVESTESSOR.

• InnaVirVax

  Participated · Equity · Jul 2015

  InnaVirVax focuses on research and development of therapeutic solutions for infectious and major chronic diseases, with an emphasis on immunotherapies. Its lead candidate, VAC-3S, is an immunotherapy intended to restore immune function in people living with HIV as part of a functional cure approach. VAC-3S is currently in a Phase 2a, randomized, double-blind, placebo-controlled study (IPROTECT1) that began in 2014 and has recruited 86 patients across 13 clinical centres in France, Germany and Spain. The company says the primary endpoint is to evaluate the immune response to three different doses of VAC-3S in adults on antiretroviral therapy. With new capital and institutional support, InnaVirVax plans to accelerate the clinical development of VAC-3S and advance the PROTHEVIH collaborative project. The company is based at the Genopole in Évry and was incorporated in 2008. InnaVirVax, founded in 2008 and based in Evry, France, focuses on therapy, prevention and prognostic solutions for AIDS/HIV, other infectious diseases, and new cancer therapies. Its lead clinical program is VAC-3S immunotherapy, which has received authorization from the AFSSAPS (the French Drug Agency). The company plans to use the new capital to conduct phase I/IIa clinical trials of VAC-3S at two Assistance Publique – Hôpitaux de Paris centers: Pitié Salpêtrière and Cochin Hospitals. InnaVirVax also intends to advance other research projects with the funding. The company is led by CEO Joël Crouzet. The announcement reports the completion of a Series B financing totaling €3.7m (approximately $4.9m).

No current team members are available.